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 The association of Epstein-Barr Virus Antibodies with Rheumatoid 
ArthritisamongYemeni patients in Sana'a city 
Abstract 
Background and objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease 
that isassociated with progressive disability, systemic complications and early death. 
Etiology of RA is unknown. It is assumed that environmental factors initiate RA 
development ingenetically susceptible individuals.Epstein-Barr Virus(EBV) stimulates 
polyclonal B cell activation and has been suggested to play a role in RA pathogenesis. 
Our study aimed tostudythe association between EBV and RA. 
Methods: One hundred and sixty subjects were enrolled in the study.Eighty individuals 
were clinically diagnosed to have RA and confirmed by anti-CCP3 test.The remaining 80 
individuals were healthy controls matched for age and sex. Serum IgG and IgM 
antibodies against EBV viral capsid antigen(VCA) weretested by anenzyme-linked 
immunosorbent assay (ELISA). 
Results: The crude prevalence rate of EBV-VCA IgM antibodies among patients was 
(21.2%)while in healthy individuals was (8.7%) with significant OR equals to 2.8 times 
for RA patient's. The female prevalence rate of EBV-VCA IgM antibodies was (21.8%) 
higher than of male(18.7%). Moreover, the crude prevalence rate of EBV-VCA IgG 
antibodies for RA patients was (91.3%) while in healthy individuals was(76.3%)with 
significant OR equals to 3.2 times for RA patients'. The female prevalence rate ofEBV-
VCA IgGantibodies was (95.3%) higher than of male(75%). 
Conclusion:EBV-VCA IgGand IgM antibodiestiters were elevated in RA patients than in 
healthy controls. However, the causative relationship between EBV and RA is complex 
and involvesdifferent mechanisms.   
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder which is common among 
females at an older age.Worldwide prevalence of RA is estimated to be about 0.5%-
1%.The cause of RA remains unclear though it has been proposedbyprevious studies that 
both genetic and environmental factors play an important role in RA pathogenesis
1-3
.RA 
genetic susceptibility is carried by HLA-DRB1* alleles containing the QK/RRAA or 
RRRAA motif in their third hypervariable region. This motif is known as the shared 
epitope
4
. It is associated with low occurrence of T cells specific for EBV gp110, a 
replicative phase glycoprotein critical for the control of EBV infection
5
. One 
environmental trigger may be the Epstein-Barr virus (EBV). 
 EBV is a double-stranded DNA herpesvirus that is extremely common 
worldwide, infecting about 98% of the human populationby the age of 40 years
6
. It is 
transmittedthrough saliva.It infects and replicates in epithelial cellsand B cells. EBV then 
becomes latent within memory B cells andpersists for the lifetime of the host
7
.It causes 
acute infectious mononucleosis. It also reported to have association with nasopharyngeal 
  
 
carcinoma, Hodgkin and non-Hodgkin lymphomas, gastric carcinoma, Burkitt lymphoma 
and other lympho-proliferative disorders in immunocompromised individuals
8
.  
 For long time, EBV has been suspected as a possibleetiology of autoimmune 
diseases including RAdue to its high prevalence in the population and its 
lifelonginfection after primary infection
9, 10
. The association between EBV and RA was 
first reported by Alspaugh and Tan. They reported that sera from RA patients were 
reactiveagainst a nuclear antigen in EBV-transformed lymphocytes
11
. Association 
between RA pathogenesis and EBV has been linked to molecular mimicry. Several EBV 
antigens share similarities with self-antigens; more specifically, glycine/alanine repeats in 
EBNA-1 resemble synovial proteins.Antibodies againstthis repeat cross-react with a 
62kD protein in RA, but not in normal synovium
12, 13
.EBV DNA loads are higherin 
mononuclear cells isolated from active RA patients compared to healthyseropositive 
individuals as well as EBV serology. Furthermore,antibodies directed against cyclic 
citrullinated peptides (ACPA) whichare used as confirmatory test for RA diagnosis, were 
found to react with acitrullinated sequence of Epstein-Barr nuclear antigen-1 (EBNA-
1),supporting the association between EBV and RA
14
. Ourstudy aimed to investigate the 
association between EBV and RA via measuring EBV-VCA IgM and IgG in RA patients 
compared with healthy controls. 
2. Subjects and methods 
This study is a case-control study conducted from October 2014 to October 2015. A total 
number of 160 individuals were included in the study. Eighty persons were clinically 
diagnosed with RA and confirmed by measuring anti-CCP3. The other 80 were healthy 
individuals used as controls. A full history from each RA case and healthy control was 
recorded on a predesigned questionnaire. The study was carried out at Al-Thawra 
Modern General Hospital and National Center of Central Public Health Laboratories, in 
Sana'a city, Yemen. Patients with other autoimmune diseases,infectious mononucleosis, 
Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, or with HIV were 
excluded from the study. 
 Five ml of venous blood was collected from each individual into plain vacationer 
tubes. The specimens were allowed to clot at room temperature and centrifuged at 3500 
rpm for five minutes. Serum was separated from each sample into Eppendorf tubes and 
stored at -20°C until tested. 
 EBV virologic assays to measure IgG and IgM viral capsid antigen (VCA) were 
performed using NovaLisaEBV ELISA kits provided by (NOVA TEC, Dietzenbach, 
Germany). The commercially ELISA test for anti-CCP3 was carried out according to the 
manufactures instructions (INOVA Diagnostics Kits, San Diego, CA-USA). Statistical 
analysis of data was performed using the Epi Info statistical program version 6 (CDC, 
Atlanta, USA). 
3. Results 
Table 1 shows the characteristics of RA patients and healthy controls. Out of 80 RA 
cases, 64 (80%) were females while 16 (20%) were males. Their age ranged from 20 to 
80 years with mean age 42.3±16.3 years old. Likewise, the control group involved 64 
(80%) females and 16 (20%) males. Their age ranged from 20 to 80 years with mean age 
39.6±11.2 years old. Most of the cases and controls were at the age group of≥50 years 
old.  
  
 
 Table 2 shows the prevalence rate of EBV-VCA IgM antibodies in different sex 
and age groups for RA patients and healthy controls. EBV-VCA IgM antibodies among 
RA females, 14 (21.8%), were higher than that of RA males, 3 (18.7%), with an OR 
equals to 2.7 times for females than males whereas in control females, 6 (9%), and males, 
1(6%). As regard to the age, the serum EBV-VCA IgM antibodies in RA patients were 
highest at the age group of 40-49, years in which the rate was (30%), followed by the age 
group of ≥50 years (25%), then the age group of 30-39 years (18.7%), and finally the age 
group of 20-29 years (13.6%). Among the controls, corresponding numbers were 1(10%), 
3(9.3%), 2(12.5%), and 1(4%), respectively. When we compared the crude prevalence 
rate of EBV IgM antibodies among cases and controls, we found that the crude 
prevalence rate among RA patients was 21.2% while among controls was 8.7%. OR of 
EBV infection for RA cases was 2.8 times, and this association was ranged from 1.01 up 
to 8.1, with significant χ2 (4.9) and statistically p equals to 0.02. 
Table 3 demonstrates the prevalence rate of EBV-VCA IgG antibodies in different 
sex and age groupsof RA patients and healthy controls. The EBV-VCA IgG antibodies 
among females, 61 (95.3%), were higher than that of males, 12 (75%), among cases with 
an OR equal to 5.2 times for females than maleswhereas, in control females, 
51(79.6%),and males, 10 (62.5%). As regard to the age, the serum EBV-VCA IgG 
antibodies were highest at the age group of ≥50 years old, in which the rate was (100%), 
followed by the age group of 40-49 years (90%), then the age group of 30-39 years 
(87.5%), and finally the age group of 20-29 years (81.8%).Among the control, 
corresponding numbers were 28(87.5%), 7(70%), 12(75%), and 14(63.6%), respectively. 
When we compared the crude prevalence rate of EBVIgG antibodies among cases and 
controls we found that the crude prevalence rate among RA patients was 91.3% while 
among controls, was 76.3%. OR of contract EBV infection for RA cases was 3.2 times, 
and this association was ranged from 1.2 up to 9.2, with significant χ2(6.6) and 
statistically p equal to 0.01. 
4. Discussion 
RA is a systemic autoimmune disease of unknown etiology. Both genetic and 
environmental factorsare suggested to contribute to RA pathogenesis 
1, 15
. Epstein-Barr 
virus was proposed as an environmental triggerof RA.It causes massive polyclonal 
expansion of resting lymphocytes and becomes latent within memory B cells for the 
lifetime of the host
16
. Thisstudy aimed to investigate the association between EBV and 
RA via measuring EBV-VCA IgM and IgG in RA patients compared with healthy 
controls. 
 Our study showed a highly significant rate and associated OR of positive EBV-
VCA IgM and IgGin RA patients than in healthy controls. Several studies have shown 
elevation of EBVantibodies in RA patients than healthy controls
14, 17, 18
. So far,there is no 
decisive theory to explain how EBV is involved in RA pathogenesis. However, several 
representative hypotheses on the possible mechanisms of EBV’s involvement in 
autoimmune diseases are described
19
. One mechanism by which EBV can trigger RA is 
molecular mimicry
20
. Studies found antibodies against EBV-encodedproteins cross-react 
with RA-specific proteins
7, 11, 21
. This finding supports the molecular mimicry hypothesis 
in RA pathogenesis either by influencing T cell receptor recognition of the HLA ‘shared 
epitope’ or through production of autoantibodies against joint antigens6. Molecular 
  
 
mimicry between a major EBV epitope and severalautoantigens might contribute to a 
breakdown of tolerance and autoimmunity in patientswith RA
22
. 
 Another possible mechanism is through autoreactive B cellstheory. It 
hypothesizes that in patients with certain autoimmune diseases,EBV infects autoreactive 
B cells leading to autoantibodies production
23, 24
. Third mechanism is through the 
mistaken-self theory. EBV-infected B cells together with closely located activated T cells 
have been demonstrated in the synovial lesions of RA
25, 26
.  
 High titers of EBV antibodies is not attributed to more frequent EBV reactivation 
in RA patients as a result of immunosuppression therapy. Studies monitored EBV viral 
load in RA patients under TNF blockers for one to five. EBV load was stable over time, 
evenwhen TNF blockers were associated with methotrexate
27-29
. 
 In conclusion, high titers of EBV antibodies are associated with RA. However, 
the causative relationship between EBV and autoimmune diseases is complex and 
involvesdifferent mechanisms. 
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Table 1: Age and sex of rheumatoid arthritis cases and healthy controls 
 
 
 
 
 
 
 
 
 
 
 
Table 2:Seropositive for EBV-VCA IgM for RA patients and healthy controls 
 
Age and Sex 
groups 
Seropositive for EBV-
VCA IgM 
OR CI χ2 
 
 
P Case Control 
No. % No. % 
Age/ Years  
20-29  3 13.6 1 4 4 0.26-9.0 1.1 0.29 
30-39  3 18.7 2 12.5 1.6 0.17-16.7 0.24 0.62 
40-49  3 30 1 10 3.8 0.24-12.1 1.25 0.26 
≥50  8 25 3 9.3 3.2 0.66-17.5 2.74 0.09 
Sex  
Female (n=64) 14 21.8 6 9 2.7 0.8-8.6 3.8 0.05 
Males (n=16) 3 18.7 1 6 3.46 0.3-9.8 1.14 0.28 
Crude rate IgM 17 21.2 7 8.7 2.8 1.01-8.1 4.9 0.02 
 
 
 
 
 
Variable Characteristics 
 
Cases (n=80) Controls(n=80) Total(n=160) 
No. % No. % No. % 
Age/ Years  
20-29  22 27.5 22 27.5 44 27.5 
30-39  16 20.0 16 20.0 32 20.0 
40-49  10 12.5 10 12.5 20 12.5 
≥50  32 40.0 32 40.0 64 40.0 
Total 80 100 80 100 160 100 
Mean/ Years 42.3 39.6 39.9 
SD/ Years 16.3 11.2 14.5 
Min./ Years 20 20  20  
Max./ Years 80 80 80 
Sex  
Females 64 80.0 64 80.0 128 80 
Males 16 20.0 16 20.0 32 20 
Total 80 100 80 100 160 100 
  
 
Table 3:Seropositive for EBV-VCA IgG for RA patients and healthy controls 
 
Age and Sex 
groups 
Case Control 
OR CI χ2 P 
No. % No. % 
Age/ Years  
20-29  18 81.8 14 63.6 2.6 0.54-13 1.8 0.17 
30-39  14 87.5 12 75 2.3 0.3-22.7 0.82 0.36 
40-49  9 90 7 70 3.86 0.24-121 1.25 0.26 
≥50  32 100 28 87.5 Undefined 4.2 0.03 
Sex  
Female (n=64) 61 95.3 51 79.6 5.2 1.28-24.4 7.14 0.007 
Males (n=16) 12 75 10 62.5 1.8 0.3-10.7 0.58 0.44 
Crude rate IgG 73 91.3 61 76.3 3.25 1.2-9.2 6.6 0.01 
 
 
 
 
 
 
 
 
 
 
